CFTR and cystic fibrosis: To date, approximately 90% of people with cystic fibrosis (pwCF) are eligible for highly-effective triple-CFTR-modulatory therapy with elexacaftor/tezacaftor/ivacaftor (ETI) as demonstrated in clinical trials or in vitro testing.